Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

ent for the control group (p=0.83) were maintained at 12 months. In addition, nine-month stent thrombosis rates for both groups were low and similar for the TAXUS Liberte Stent (0.8 percent) and control stent (0.7 percent, p=1.0).

"ATLAS clinical outcomes highlight that despite more complex lesions, the TAXUS Liberte Stent performed extremely well and achieved similar rates of death, myocardial infarction and repeat procedures compared to an historical TAXUS Express control," said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, Takoma Park, Maryland, and co-principal investigator of the TAXUS ATLAS trial.

Data reported in the JACC article showed the TAXUS Liberte Stent was associated with significantly shorter procedural times. The study documented shorter average procedure times of 47.8 minutes for TAXUS Liberte Stent versus 53.0 minutes in the control arm (p=0.0052). The need to use additional stents due to procedural complications was reduced by nearly 50 percent in the TAXUS Liberte Stent group (3.1 percent) versus control (6.0 percent) (p=0.0038).

"The TAXUS Liberte Stent represents the latest innovation of our drug-eluting stent pipeline and we are pleased that the TAXUS ATLAS results confirm its positive performance," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "It is also further testament to the leadership of Boston Scientific that we are able to take a proven drug like paclitaxel and successfully transition it to an even more deliverable platform such as the Liberte Stent."

The Company received the CE Mark for the TAXUS Liberte stent in Europe and other international markets in September 2005, and it is currently the market-leading drug-eluting stent outside the United States. The TAXUS Liberte stent is currently pending approval by the U.S. Food and Drug Administration and is not available for sale in the United States.

Boston
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle ... makers of medical devices. As part of its ... in EMEA concentrates on the EMEA medical device ...
(Date:8/20/2014)... Reportlinker.com announces that ... its catalogue: EMR 2014: The Market ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously examined ... for nearly a decade, and each year we ... report has become the industry standard, oft-quoted by ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8
... Aug. 25, 2011 BioRestorative Therapies, Inc. ... into a Tangible Property License Agreement with the University ... Therapies to obtain adipose (fat) tissue that will be ... ThermoStem Program , which is an adult derived ...
... ePharmaSolutions announced the successful deployment of its Enterprise ... global pharmaceutical company on more than 900 studies to ... September 2011. Clinical Trial Portals help streamline ... sites and third party vendors by providing a common ...
Cached Medicine Technology:BioRestorative Therapies Signs License Agreement With University of Utah to Obtain Adipose (Fat) Tissue for its ThermoStem Program to Treat Obesity and Metabolic Disorders 2ePharmaSolutions Announces the Deployment of its Enterprise Clinical Trial Portal for Two Global Biopharmaceutical Companies 2
(Date:8/20/2014)... Tuberculosis is one of the most persistent and deadliest ... million people each year. , Scientists who study tuberculosis ... tuberculosis likely spread from humans in Africa to seals ... America and transmitted it to Native people there before ... Mycobacterial Genomes Reveal Seals as a Source of New ...
(Date:8/20/2014)... spawning grounds through fast-moving waters may be at risk, ... , When salmon encounter turbulent, fast-moving water such ... must move upstream using a behaviour known as "burst ... "Days after sockeye passed through extremely fast-moving water, we ... from their spawning grounds," said Nicholas Burnett, a research ...
(Date:8/20/2014)... York (PRWEB) August 20, 2014 As ... use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... that two U.S. Senators from New York are urging ... a recall of the devices. In a letter dated ... Democrats, also implored the agency to seriously consider the ...
(Date:8/20/2014)... 2014) Research from Columbia University Medical Center shows ... cancer growth and that blocking nerve signals using surgery ... the disease. The study was conducted by the laboratory ... Chen, MD, PhD, in Norway and is published in ... "Scientists have long observed that human and mouse cancers ...
(Date:8/20/2014)... stimulates stress responses in adults, researchers at Yerkes ... that the amygdala has an inhibitory effect on ... primates. , The results are published this week ... amygdala is a region of the brain known ... and learning about threats. Alterations in the amygdala ...
Breaking Medicine News(10 mins):Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
... that Migration/Macrophage Inhibitory factor (MIF) which is an immune cell ... be used in finding drugs which reduces the amount of ... hindered. , Multiple Sclerosis: ,Multiple ... of its own body cells by the immune system leading ...
... A recent study published in the November issue ... that dyspnea, or shortness of breath may be ... ,Although dyspnea is a common symptom, there ... significance among patients referred for cardiac evaluation.,Cardiologists at ...
... plethora of medicinal properties it is a great food. ... such as vampires. Now scientists are finding that garlic, //or ... carcinogens produced by meat cooked at high temperatures. ... releases a chemical called PhIP, a suspected carcinogen. Epidemiological studies ...
... broccoli sprouts may help prevent gastric cancer by reducing Helicobacteri ... and is believed to be a major factor in peptic ... a Japanese team, found that taking a diet with 100 ... H. pylori infection experiencing a significant reduction of H. pylori ...
... Dr. Wan Lian Chua, Psychiatrist, Bradford District Care Trust ... had not given any effective improvement in their condition. ... use of estrogen therapy for treatment of Schizophrenia. Researchers ... used in treating patients before it is tested in ...
... Avian flu pandemic could kill 3 million people in Asia, ... a recession in the world, the Asian Development Bank has ... the likely effects on the region if bird flu produces ... workers being taken ill. 'Growth in Asia would virtually stop,' ...
Cached Medicine News:Health News:Macrophage Inhibitory Factor Causes Multiple Sclerosis Progression 2Health News:A Boon For Gastritis Patients In The Form Of Broccoli 2Health News:ADB Report Warns of Bird-Flu Catastrophe 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: